AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ABBV
  • CUSIP: 00287Y10
  • Web:
  • Market Cap: $136.00819 billion
  • Outstanding Shares: 1,594,094,000
Average Prices:
  • 50 Day Moving Avg: $75.76
  • 200 Day Moving Avg: $69.87
  • 52 Week Range: $55.06 - $89.69
  • Trailing P/E Ratio: 21.24
  • Foreward P/E Ratio: 13.13
  • P/E Growth: 1.12
Sales & Book Value:
  • Annual Revenue: $26.71 billion
  • Price / Sales: 5.15
  • Book Value: $3.77 per share
  • Price / Book: 22.91
  • Annual Dividend: $2.56
  • Dividend Yield: 3.0%
  • EBIDTA: $11.57 billion
  • Net Margins: 24.77%
  • Return on Equity: 150.27%
  • Return on Assets: 12.52%
  • Debt-to-Equity Ratio: 5.63%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.25%
  • Average Volume: 5.91 million shs.
  • Beta: 1.48
  • Short Ratio: 5.37

Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, September 8th. Shareholders of record on Friday, October 13th will be given a dividend of $0.64 per share on Wednesday, November 15th. This represents a $2.56 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend is Thursday, October 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has authorized a share buyback program on Sunday, April 9th 2017, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 5% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, July, 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company's quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.26 EPS. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY17 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

13 brokerages have issued twelve-month price targets for AbbVie's shares. Their forecasts range from $60.00 to $107.00. On average, they expect AbbVie's share price to reach $83.75 in the next twelve months. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
  • 2. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
  • William J. Chase, Executive Vice President, Chief Financial Officer
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
  • Carlos Alban, Executive Vice President - Commercial Operations
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
  • Timothy J. Richmond, Senior Vice President - Human Resources
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
  • Robert A. Michael, Vice President, Controller
  • Robert J. Alpern M.D., Independent Director

Who owns AbbVie stock?

AbbVie's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.18%), Vanguard Group Inc. (7.28%), BlackRock Inc. (5.91%), State Street Corp (4.48%), Northern Trust Corp (1.33%) and Bank of New York Mellon Corp (1.07%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Glenview Capital Management LLC, Bank of New York Mellon Corp, Canada Pension Plan Investment Board, AXA, APG Asset Management N.V., Prudential PLC and Strs Ohio. Company insiders that have sold AbbVie stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Janus Henderson Group PLC, Orbis Allan Gray Ltd, Capital Research Global Investors, BlackRock Inc., Prudential Financial Inc., Balyasny Asset Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $86.37.

MarketBeat Community Rating for AbbVie (NYSE ABBV)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  585 (Vote Outperform)
Underperform Votes:  331 (Vote Underperform)
Total Votes:  916
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.54)
Consensus Price Target: $83.75 (3.03% downside)

Analysts' Ratings History for AbbVie (NYSE:ABBV)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Jefferies Group LLCReiterated RatingBuy -> Buy$94.00 -> $107.00HighView Rating Details
9/15/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00HighView Rating Details
9/13/2017SunTrust Banks, Inc.Reiterated RatingBuy$95.00LowView Rating Details
9/12/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
9/11/2017Cowen and CompanyReiterated RatingMarket Perform -> Hold$70.00 -> $95.00MediumView Rating Details
9/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$85.00 -> $100.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$95.00MediumView Rating Details
7/20/2017Credit Suisse GroupReiterated RatingNeutral$65.00 -> $74.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$65.00 -> $66.00LowView Rating Details
6/22/2017Societe GeneraleUpgradeHold -> BuyLowView Rating Details
5/17/2017BMO Capital MarketsReiterated RatingMarket Perform$66.00LowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
8/8/2016ArgusReiterated RatingBuy$85.00N/AView Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$68.00N/AView Rating Details
6/8/2016Morgan StanleyDowngradeOverweight -> Equal Weight$73.00 -> $65.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for AbbVie (NYSE:ABBV)
Earnings by Quarter for AbbVie (NYSE:ABBV)
Earnings History by Quarter for AbbVie (NYSE ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$1.38N/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.52 EPS
Next Year EPS Consensus Estimate: $6.58 EPS


Current Dividend Information for AbbVie (NYSE:ABBV)
Next Dividend:11/15/2017
Annual Dividend:$2.56
Dividend Yield:2.96%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:62.90% (Trailing 12 Months of Earnings)
46.38% (Based on This Year's Estimates)
38.91% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.25%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.00View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.00View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.00View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
DateHeadline logoRoche (RHHBY) Announces Positive Data on Leukemia Drug - September 19 at 8:20 PM logoAbbVie Joins $30 Million Financing Round For Disarm Therapeutics - Seeking Alpha - September 19 at 3:19 PM logoVenclexta/Rituxan combo successful in late-stage CLL study - Seeking Alpha - September 18 at 3:24 PM logoJ&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU - September 18 at 3:24 PM logoAbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - September 18 at 3:24 PM logoCritical Analysis: Eagle Pharmaceuticals (EGRX) vs. AbbVie (ABBV) - September 18 at 10:36 AM logoAbbVie: Bullish Institutional Buying To Send The Stock Higher - Seeking Alpha - September 16 at 3:15 PM logoAbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share - September 15 at 3:14 PM logoAbbVie Inc. (ABBV) Given "Overweight" Rating at Piper Jaffray Companies - September 15 at 7:28 AM logoAbbVie's (ABBV) "Top Pick" Rating Reiterated at Jefferies Group LLC - September 15 at 7:28 AM logoComparing AbbVie (ABBV) and Its Competitors - September 14 at 4:16 PM logoHow Safe Is Abbott Labs' Dividend? - September 14 at 3:18 PM logoNovartis Announces Long-Term Data on Psoriasis Drug Cosentyx - September 14 at 3:18 PM logoToday's Research Reports on Trending Tickers: AbbVie and Intercept Pharmaceuticals - September 14 at 1:24 AM logo5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing - September 14 at 1:24 AM logoCramer's lightning round: Here's where Qualcomm went wrong - September 14 at 1:24 AM logoCramer's lightning round: Here's where Qualcomm went wrong - September 13 at 8:20 PM logoCramer's lightning round: Here's where Qualcomm went wron... - September 13 at 8:20 PM logoAbbVie Inc. (ABBV) Earns Buy Rating from SunTrust Banks, Inc. - September 13 at 3:34 PM logoMarket Finally Realizing AbbVie's Value - Seeking Alpha - September 13 at 3:17 PM logoBiotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data - September 13 at 3:17 PM logoAbbVie Is Likely to Correct: Book Some Profits - September 13 at 3:17 PM logo5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing - September 13 at 7:08 AM logoAbbVie's upadacitinib successful in late-stage RA study - Seeking Alpha - September 12 at 8:18 PM logoAbbVie Inc. (ABBV) SVP Azita Saleki-Gerhardt Sells 8,300 Shares - September 12 at 7:34 PM logoAbbVie: Not For The Faint Of Heart - September 12 at 3:16 PM logoAbbVie's RA Candidate Meets Primary Endpoint in Phase III - September 12 at 3:16 PM logoAbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis - September 12 at 1:48 AM logoWhy Achillion Pharmaceuticals Crashed 22.2% Today - September 11 at 8:47 PM logoUPDATE 1-AbbVie reports two patient deaths in rheumatoid arthritis study - Reuters - September 11 at 3:44 PM logoAbbVie says deaths in arthritis trial not linked to drug - Reuters - September 11 at 3:44 PM logoAbbVie reports two patient deaths in rheumatoid arthritis study - Reuters - September 11 at 3:44 PM logoAbbVie says deaths in arthritis trial not linked to drug - September 11 at 3:44 PM logoRegeneron: When Good Isn't Good Enough - September 11 at 3:44 PM logoAbbVie's upadacitinib successful in late-stage RA study - September 11 at 12:49 PM logoAbbVie Inc. (ABBV) Receives Hold Rating from Cowen and Company - September 11 at 8:22 AM logo$6.97 Billion in Sales Expected for AbbVie Inc. (ABBV) This Quarter - September 11 at 3:30 AM logoAbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb - September 10 at 8:19 PM logoAbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher - September 10 at 8:19 PM logoAbbVie Inc. (ABBV) Expected to Announce Earnings of $1.37 Per Share - September 9 at 4:26 PM logo3 Stocks That Put Walt Disney's Returns to Shame - September 9 at 3:15 PM logoAbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from Analysts - September 9 at 12:40 PM logoAbbVie Inc. (ABBV) Earns "Buy" Rating from Goldman Sachs Group, Inc. (The) - September 8 at 10:34 PM logoJefferies Group LLC Reaffirms Buy Rating for AbbVie Inc. (ABBV) - September 8 at 9:52 PM logoRegeneron's Cemiplimab Gains Breakthrough Therapy Status - September 8 at 8:28 PM logoAbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb - September 8 at 8:28 PM logoAbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher - Nasdaq - September 8 at 3:24 PM logoAbbVie's Patent Win And How It Benefits Long-Term Investors - Seeking Alpha - September 8 at 3:24 PM logoThe case for GlaxoSmithKline - Motley Fool - September 8 at 3:24 PM logoAbbVie: Up, Up and Away! - September 8 at 3:24 PM



AbbVie (ABBV) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff